All In Biotech

Drug Trial Radar · NCT01414075

Study of Roxadustat (FG-4592) to Correct Anemia in Newly Initiated Dialysis Participants Not on Erythropoiesis-Stimulating Agent Treatment

A Phase 2, Randomized, Open-Label, Dose Titration, Safety and Efficacy Study of FG-4592 for the Correction of Anemia in Newly Initiated Dialysis Patients Not on Erythropoiesis-Stimulating Agent Treatment

Last checked: Nov 20, 2026Latest source record: Oct 1, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

60

Actual

Start

Jul 21, 2011

Primary completion

Jan 10, 2013

Study completion Jan 10, 2013

Sponsor

Lead sponsor
Kyntra BioIndustry
Sponsor type
Industry
Collaborators
Astellas Pharma Inc
First posted
Aug 11, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate efficacy and safety of roxadustat in the correction of anemia in participants with end-stage renal disease who recently started dialysis.

Conditions

  • Dialysis
  • Anemia

Interventions

  • RoxadustatDrug

    Tiered, weight-based dosing per schedule specified in the arm.

  • Oral IronDrug

    Administered per oral dose and schedule specified in the arm.

  • IV IronDrug

    Administered per IV dose and schedule specified in the arm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Change From Baseline in Hb During Weeks 3-13Time frame: Baseline, Weeks 3-13

Locations

7 sites in 4 countries. Site status is shown where the registry gives one.

  • Site not named

    Northridge, California

  • Site not named

    Yuba City, California

  • Site not named

    Detroit, Michigan

  • Site not named

    Hong Kong, Hong Kong

  • Site not named

    Moscow, Russia

  • Site not named

    Saint Petersburg, Russia

  • Site not named

    Singapore, Singapore

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.